Edding Genor Group (HKG:6998) completed the first subject dosing in a phase Ib/II clinical trial of GB268, according to a Thursday Hong Kong bourse said.
Shares of the company were up nearly 4% in Friday afternoon trading.
The drug is for the treatment of locally advanced unresectable or metastatic breast cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.